Sci­en­tists toss an­oth­er Alzheimer’s pro­gram in­to the scrap heap as PhII fails

While a le­gion of sci­en­tists have been em­ployed in failed at­tempts to clear away the tox­ic tan­gles of pro­teins of­ten found in the brains of Alzheimer’s pa­tients, an­oth­er set have con­tin­ued to plug away at the var­i­ous chem­i­cals that play a role in or­ches­trat­ing the brain’s com­plex cel­lu­lar com­mu­ni­ca­tions sys­tem.

But that’s proved just as frus­trat­ing.

Jan Poth

To­day, Boehringer In­gel­heim threw in the tow­el on an Alzheimer’s pro­gram for a drug called BI 409306, an­oth­er ef­fort to see if they could do a bet­ter job in mod­u­lat­ing glu­ta­mate, one of those neu­ro­trans­mit­ters that can run amuck in de­men­tia.

The drug works by block­ing a pro­tein called PDE 9A which they be­lieved would en­hance cell sig­nal­ing in the glu­ta­mater­gic com­mand cen­ter in the brain. Re­searchers re­cruit­ed 457 pa­tients for two stud­ies, but like every­thing else that’s been put to a de­fin­i­tive test in the past 15 years, it failed to beat a place­bo in im­prov­ing cog­ni­tion.

It’s a log­i­cal field to ex­plore. Na­men­da was ap­proved by the FDA 15 years ago af­ter it was brought in from Eu­rope, where it had been used for years. That’s a glu­ta­mater­gic drug, fo­cus­ing on the NM­DA re­cep­tor — a big play­er in de­pres­sion. The drug tem­porar­i­ly mod­u­lates cog­ni­tive symp­toms of a dis­ease that grad­u­al­ly wipes out mem­o­ries.

Boehringer hasn’t giv­en up on the drug. It has plans to test it in schiz­o­phre­nia. And there’s a GlyT1 in­hibitor — an­oth­er glu­ta­mate drug called BI 425809 — which is be­ing test­ed in Alzheimer’s and oth­er CNS dis­eases.

The fail­ure rate for Alzheimer’s drug has been run­ning par­tic­u­lar­ly hot of late. We re­cent­ly got a close look at just how bad­ly Eli Lil­ly’s solanezum­ab failed to al­ter the course of the dis­ease by fo­cus­ing on amy­loid be­ta. Ax­o­vant cratered af­ter back-to-back fail­ures on a 5HT6 drug, an­oth­er symp­to­matic ef­fort fo­cused on a key neu­ro­trans­mit­ter. And Pfiz­er capped off the string of set­backs by call­ing it quits in the field, wip­ing out a pipeline of drugs and lay­ing off 300 peo­ple work­ing in the area.

Big play­ers like Bio­gen, though, con­tin­ue to in­vest heav­i­ly, con­vinced that they can suc­ceed where all oth­ers failed. And an up­start like De­nali can pull off a record-set­ting IPO by promis­ing to pur­sue new strate­gies.

But the odds in this field are par­tic­u­lar­ly tough, in an in­dus­try where fail­ure is a dai­ly re­al­i­ty.

“We recog­nise the im­mense an­tic­i­pa­tion around any progress in brain re­search that brings us clos­er to find­ing so­lu­tions for the many mil­lions of peo­ple liv­ing with de­men­tia. How­ev­er, this is what re­search is about: dis­ap­point­ments are a dai­ly ex­pe­ri­ence in sci­ence, but even these clin­i­cal tri­al re­sults will add to the un­der­stand­ing of brain func­tion and con­tribute to fu­ture progress in this area.” said Jan Poth, ther­a­peu­tic area head of CNS and im­munol­o­gy at Boehringer In­gel­heim.

Paul Hudson, Sanofi CEO (Getty Images)

Sanofi CEO Paul Hud­son has $23B burn­ing a hole in his pock­et. And here are some hints on how he plans to spend that

Sanofi has reaped $11.1 billion after selling off a big chunk of its Regeneron stock at $515 a share. And now everyone on the M&A side of the business is focused on how CEO Paul Hudson plans to spend it.

After getting stung in France for some awkward politicking — suggesting the US was in the front of the line for Sanofi’s vaccines given American financial support for their work, versus little help from European powers — Hudson now has the much more popular task of managing a major cash cache to pull off something in the order of a big bolt-on. Or two.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,400+ biopharma pros reading Endpoints daily — and it's free.

The Advance Clinical leadership team: CEO Yvonne Lungershausen, Sandrien Louwaars - Director Business Development Operations, Gabriel Kremmidiotis - Chief Scientific Officer, Ben Edwards - Chief Strategy Officer

How Aus­tralia De­liv­ers Rapid Start-up and 43.5% Re­bate for Ear­ly Phase On­col­o­gy Tri­als

About Avance Clinical

Avance Clinical is an Australian owned Contract Research Organisation that has been providing high-quality clinical research services to the local and international drug development industry for 20 years. They specialise in working with biotech companies to execute Phase 1 and Phase 2 clinical trials to deliver high-quality outcomes fit for global regulatory standards.

As oncology sponsors look internationally to speed-up trials after unprecedented COVID-19 suspensions and delays, Australia, which has led the world in minimizing the pandemic’s impact, stands out as an attractive destination for early phase trials. This in combination with the streamlined regulatory system and the financial benefits including a very favourable exchange rate and the R & D cash rebate makes Australia the perfect location for accelerating biotech clinical programs.

Pablo Legorreta, founder and CEO of Royalty Pharma AG, speaks at the annual Milken Institute Global Conference in Beverly Hills, California (Patrick T. Fallon/Bloomberg via Getty Images)

Cap­i­tal­iz­ing Pablo: The world’s biggest drug roy­al­ty buy­er is go­ing pub­lic. And the low-key CEO di­vulges a few se­crets along the way

Pablo Legorreta is one of the most influential players in biopharma you likely never heard of.

Over the last 24 years, Legorreta’s Royalty Pharma group has become, by its own reckoning, the biggest buyer of drug royalties in the world. The CEO and founder has bought up a stake in a lengthy list of the world’s biggest drug franchises, spending $18 billion in the process — $2.2 billion last year alone. And he’s become one of the best-paid execs in the industry, reaping $28 million from the cash flow last year while reserving 20% of the cash flow, less expenses, for himself.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,400+ biopharma pros reading Endpoints daily — and it's free.

Dan O'Day, Gilead CEO (Andrew Harnik, AP Images)

UP­DAT­ED: Gilead leas­es part­ner rights to TIG­IT, PD-1 in a $2B deal with Ar­cus. Now comes the hard part

Gilead CEO Dan O’Day has brokered his way to a PD-1 and lined up a front row seat in the TIGIT arena, inking a deal worth close to $2 billion to align the big biotech closely with Terry Rosen’s Arcus. And $375 million of that comes upfront, with cash for the buy-in plus equity, along with $400 million for R&D and $1.22 billion in reserve to cover opt-in payments and milestones..

Hotly rumored for weeks, the 2 players have formalized a 10-year alliance that starts with rights to the PD-1, zimberelimab. O’Day also has first dibs on TIGIT and 2 other leading programs, agreeing to an opt-in fee ranging from $200 million to $275 million on each. There’s $500 million in potential TIGIT milestones on US regulatory events — likely capped by an approval — if Gilead partners on it and the stars align on the data. And there’s another $150 million opt-in payments for the rest of the Arcus pipeline.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,400+ biopharma pros reading Endpoints daily — and it's free.

Bryan Roberts, Venrock

Ven­rock sur­vey shows grow­ing recog­ni­tion of coro­n­avirus toll, wan­ing con­fi­dence in ar­rival of vac­cines and treat­ments

When Venrock partner Bryan Roberts went to check the results from their annual survey of healthcare leaders, what he found was an imprint of the pandemic’s slow arrival in America.

The venture firm had sent their form out to hundreds of insurance and health tech executives, investors, officials and academics on February 24 and gave them two weeks to fill it out. No Americans had died at that point but the coronavirus had become enough of a global crisis that they included two questions about the virus, including “Total U.S. deaths in 2020 from the novel coronavirus will be:”.

Roger Perlmutter, Merck R&D chief (YouTube)

UP­DAT­ED: Backed by BAR­DA, Mer­ck jumps in­to Covid-19: buy­ing out a vac­cine, part­ner­ing on an­oth­er and adding an­tivi­ral to the mix

Merck execs are making a triple play in a sudden leap into the R&D campaign against Covid-19. And they have more BARDA cash backing them up on the move.

Tuesday morning the pharma giant simultaneously announced plans to buy an Austrian biotech that has been working on a preclinical vaccine candidate, added a collaboration on another vaccine with the nonprofit IAVI and inked a deal with Ridgeback Biotherapeutics on an early-stage antiviral.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,400+ biopharma pros reading Endpoints daily — and it's free.

David Hoey (Vaxxas)

In for the long vac­cine game, Mer­ck buys in­to patch de­liv­ery tech with pan­dem­ic po­ten­tial

When Merck dived into the R&D fray for a Covid-19 vaccine earlier this week, execs made it clear that they’re not necessarily looking to be first — with CEO Ken Frazier throwing cold water on the hotly-discussed 12- to 18-month timelines. But when it does emerge from behind, the pharma giant clearly expects to play a significant part.

Part of that will depend on next-generation delivery technology that reshapes the world’s imagination of a vaccine.

No­var­tis jumps in­to Covid-19 vac­cine hunt, as Big Phar­ma and big biotech com­mit to bil­lions of dos­es

After spending most of the pandemic on the sidelines, Novartis is offering its aid in the race to develop a Covid-19 vaccine.

AveXis, the Swiss pharma’s gene therapy subsidiary, has agreed to manufacture the vaccine being developed by Massachusetts Eye and Ear and Massachusetts General Hospital. The biotech will begin manufacturing this month, while the vaccine undergoes further preclinical testing. They’ve agreed to provide the vaccine for free for clinical trials beginning in the second half of 2020, but have not disclosed financials for after.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,400+ biopharma pros reading Endpoints daily — and it's free.

De­nali un­veils new way of cross­ing blood brain bar­ri­er as the big neu­ro­science bet en­ters its clin­i­cal years

Five years ago, as much of pharma began leaving neuroscience, three big-name scientists from Genentech and some A-list investors, including ARCH and Flagship, made a $217 million bet that new genetic insights and a reliance on biomarkers could bring them success. They called it Denali Therapeutics.

Still, Denali faced the problem that neuroscience developers have faced for decades: How do you get a large molecule across the blood-brain barrier, a natural defense evolved precisely to keep them out? Enzyme replacement therapy, for instance, would be a great candidate to treat several neurological disorders, but enzymes can’t cross the barrier.